Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

SGYP 9.12 +0.53 (6.17%)
price chart
Shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Sees Large Outflow of Money
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) surged 4.63% during the last session. The last traded price was up 0.38 points at $8.59.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced positive top-line ...  Inside Trade
Canaccord Reiterates Bullish Stance On Synergy Pharmaceuticals Inc (SGYP ...  Smarter Analyst
Synergy Pharmaceuticals Inc (SGYP) Jumps 6.17% on July 31
Synergy Pharmaceuticals Inc (SGYP) was among the biggest gainers on the Russell 2000 for Friday July 31 as the stock popped 6.17% to $9.12, representing a gain of $0.53 per share.
Stocks on the Move: MannKind Corporation, Synergy Pharmaceuticals Inc, Unilife ...
Another sector garnering notable attention today is healthcare, with several components -- including biotechs MannKind Corporation (NASDAQ:MNKD) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP), as well as medical device maker Unilife Corp ...
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Short Interest Update
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has witnessed a rise of 15.5% or 3,390,448 shares in its short figure. The short interest augmentation took it from 21,885,645 on June 30,2015 to 25,276,093 on July 15,2015.
Small Cap Stocks in Queue - Synergy Pharmaceuticals Inc (SGYP), Pengrowth ...  Techsonian (press release)
Active Stocks Under Consideration: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP ...
Synergy Pharmaceuticals declared positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1337 ...
Benzinga's Top #PreMarket Gainers
Synergy Pharmaceuticals Inc (NASDAQ: SGYP) shares climbed 18.76 percent to $9.75 in pre-market trading following the announcement of positive results in second Phase 3 trial of plecanatide in patients with CIC.
Zacks Rating on Synergy Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) remains a strong buy in the latest set of rankings. The shares has received an average rating of 1 by 2 analysts.
Company Shares of Synergy Pharmaceuticals, Inc. Rally 12.9%  OTC Outlook
Short Interest Update of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
The short interest in Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has increased from 21,533,220 on June 15,2015 to 21,885,645 on June 30,2015.
Synergy Pharmaceuticals Downgraded by Zacks to Hold (SGYP)  Dakota Financial News
Company Shares of Synergy Pharmaceuticals, Inc. Drops by -12.21%
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has lost 12.21% during the past week and dropped 3.77% in the last 4 weeks.
Mid-Day Changers: Synergy Pharmaceuticals, Inc. (SGYP), Hallador Energy ...  WallStreet Scope
Biotech Beat: MannKind Corporation (MNKD), Synergy Pharmaceuticals Inc (SGYP ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has been a major topic of conversation in the biotech space after producing overwhelmingly positive results in their Phase 3 study of plecanatide.